Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Dermatology | 70 | 2025 | 905 | 20.710 |
Why?
|
Psoriasis | 10 | 2024 | 926 | 4.100 |
Why?
|
Skin Diseases | 13 | 2023 | 1085 | 3.660 |
Why?
|
Internship and Residency | 29 | 2024 | 5953 | 3.520 |
Why?
|
Skin Neoplasms | 21 | 2024 | 5863 | 2.960 |
Why?
|
Lupus Erythematosus, Discoid | 3 | 2024 | 61 | 2.180 |
Why?
|
Lupus Erythematosus, Cutaneous | 4 | 2023 | 75 | 2.170 |
Why?
|
Drug Eruptions | 4 | 2024 | 335 | 2.120 |
Why?
|
Pyoderma Gangrenosum | 3 | 2023 | 84 | 2.040 |
Why?
|
Skin Pigmentation | 5 | 2024 | 280 | 1.880 |
Why?
|
Vitiligo | 3 | 2024 | 97 | 1.760 |
Why?
|
Consumer Health Information | 3 | 2024 | 215 | 1.600 |
Why?
|
Career Choice | 7 | 2022 | 769 | 1.570 |
Why?
|
Schools, Medical | 6 | 2024 | 883 | 1.560 |
Why?
|
Hemochromatosis | 2 | 2023 | 175 | 1.500 |
Why?
|
Education, Medical, Undergraduate | 7 | 2024 | 1085 | 1.480 |
Why?
|
Pityriasis Rubra Pilaris | 2 | 2021 | 20 | 1.440 |
Why?
|
Exanthema | 4 | 2024 | 503 | 1.410 |
Why?
|
Melanoma | 8 | 2024 | 5706 | 1.410 |
Why?
|
Remote Consultation | 3 | 2021 | 242 | 1.370 |
Why?
|
Education, Medical, Graduate | 9 | 2024 | 2420 | 1.350 |
Why?
|
Humans | 191 | 2025 | 768171 | 1.270 |
Why?
|
Telemedicine | 8 | 2023 | 3109 | 1.220 |
Why?
|
Dermatomyositis | 2 | 2022 | 259 | 1.150 |
Why?
|
Skin Diseases, Genetic | 2 | 2024 | 49 | 1.090 |
Why?
|
Oncolytic Virotherapy | 2 | 2024 | 520 | 1.070 |
Why?
|
Clinical Clerkship | 3 | 2018 | 569 | 1.060 |
Why?
|
Acne Vulgaris | 2 | 2022 | 352 | 1.050 |
Why?
|
Comprehension | 4 | 2025 | 638 | 1.000 |
Why?
|
Documentation | 4 | 2021 | 917 | 1.000 |
Why?
|
United States | 46 | 2025 | 73039 | 0.960 |
Why?
|
Collagen Diseases | 1 | 2024 | 39 | 0.940 |
Why?
|
Dermatologic Agents | 4 | 2025 | 313 | 0.940 |
Why?
|
Lupus Erythematosus, Systemic | 4 | 2023 | 2171 | 0.920 |
Why?
|
Pruritus | 2 | 2024 | 379 | 0.900 |
Why?
|
Ecthyma | 1 | 2023 | 8 | 0.880 |
Why?
|
Spondylarthropathies | 1 | 2023 | 14 | 0.880 |
Why?
|
Hereditary Autoinflammatory Diseases | 1 | 2024 | 42 | 0.880 |
Why?
|
Anemia | 2 | 2023 | 1514 | 0.870 |
Why?
|
Hyperpigmentation | 2 | 2023 | 116 | 0.870 |
Why?
|
Hidradenitis Suppurativa | 2 | 2024 | 176 | 0.860 |
Why?
|
Skin | 9 | 2024 | 4505 | 0.830 |
Why?
|
Lichen Nitidus | 1 | 2022 | 4 | 0.830 |
Why?
|
Sunburn | 1 | 2024 | 156 | 0.830 |
Why?
|
Skin Diseases, Vesiculobullous | 1 | 2023 | 83 | 0.820 |
Why?
|
Curriculum | 7 | 2024 | 3782 | 0.820 |
Why?
|
Foot Diseases | 3 | 2021 | 148 | 0.820 |
Why?
|
Supreme Court Decisions | 1 | 2024 | 135 | 0.810 |
Why?
|
Medicine, Traditional | 2 | 2021 | 89 | 0.810 |
Why?
|
Burnout, Professional | 2 | 2021 | 711 | 0.800 |
Why?
|
Lasers, Gas | 1 | 2023 | 104 | 0.790 |
Why?
|
Lymphoma, B-Cell | 2 | 2019 | 945 | 0.790 |
Why?
|
Urban Health Services | 2 | 2021 | 177 | 0.790 |
Why?
|
Investments | 2 | 2022 | 149 | 0.790 |
Why?
|
Students, Medical | 6 | 2024 | 1964 | 0.770 |
Why?
|
Music Therapy | 1 | 2023 | 111 | 0.760 |
Why?
|
Artificial Intelligence | 4 | 2024 | 2666 | 0.760 |
Why?
|
Personnel Selection | 2 | 2024 | 201 | 0.750 |
Why?
|
Lasers, Solid-State | 1 | 2023 | 184 | 0.750 |
Why?
|
Foreign Medical Graduates | 1 | 2022 | 76 | 0.750 |
Why?
|
Glucagon-Like Peptide 1 | 1 | 2024 | 374 | 0.750 |
Why?
|
Vulnerable Populations | 3 | 2021 | 718 | 0.740 |
Why?
|
Sleep Apnea, Obstructive | 2 | 2024 | 1899 | 0.730 |
Why?
|
Sclerosis | 1 | 2021 | 211 | 0.730 |
Why?
|
Mohs Surgery | 1 | 2023 | 217 | 0.720 |
Why?
|
Music | 1 | 2023 | 247 | 0.700 |
Why?
|
Medically Underserved Area | 2 | 2022 | 268 | 0.690 |
Why?
|
Webcasts as Topic | 1 | 2020 | 21 | 0.680 |
Why?
|
Stevens-Johnson Syndrome | 3 | 2024 | 232 | 0.680 |
Why?
|
Skin Diseases, Infectious | 1 | 2020 | 75 | 0.680 |
Why?
|
Mongolian Spot | 1 | 2019 | 3 | 0.670 |
Why?
|
Erythema Multiforme | 1 | 2019 | 31 | 0.660 |
Why?
|
Paraneoplastic Syndromes | 2 | 2020 | 154 | 0.660 |
Why?
|
Cross-Sectional Studies | 16 | 2024 | 26379 | 0.640 |
Why?
|
Intestinal Neoplasms | 1 | 2021 | 314 | 0.630 |
Why?
|
HIV Seronegativity | 1 | 2019 | 210 | 0.630 |
Why?
|
Pseudomonas Infections | 1 | 2023 | 623 | 0.630 |
Why?
|
Specialty Boards | 1 | 2020 | 235 | 0.620 |
Why?
|
Indians, North American | 1 | 2022 | 354 | 0.620 |
Why?
|
Calcitriol | 2 | 2021 | 303 | 0.620 |
Why?
|
Referral and Consultation | 3 | 2020 | 3620 | 0.620 |
Why?
|
Interleukins | 1 | 2023 | 796 | 0.610 |
Why?
|
Hospitals, University | 1 | 2020 | 570 | 0.610 |
Why?
|
Immunologic Techniques | 1 | 2018 | 213 | 0.610 |
Why?
|
Immunoconjugates | 2 | 2024 | 975 | 0.600 |
Why?
|
Skin Diseases, Papulosquamous | 1 | 2017 | 17 | 0.590 |
Why?
|
Carcinoma, Basal Cell | 1 | 2023 | 565 | 0.580 |
Why?
|
Chronic Disease | 6 | 2023 | 9384 | 0.580 |
Why?
|
Medical Informatics | 2 | 2024 | 743 | 0.570 |
Why?
|
Private Practice | 1 | 2018 | 154 | 0.570 |
Why?
|
Edema | 1 | 2021 | 765 | 0.570 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2024 | 794 | 0.570 |
Why?
|
Hemangiosarcoma | 1 | 2019 | 215 | 0.560 |
Why?
|
Faculty, Medical | 4 | 2019 | 1226 | 0.560 |
Why?
|
Certification | 1 | 2020 | 420 | 0.560 |
Why?
|
Immunologic Factors | 3 | 2016 | 1596 | 0.560 |
Why?
|
Hair | 1 | 2020 | 508 | 0.550 |
Why?
|
Rural Health Services | 1 | 2021 | 394 | 0.550 |
Why?
|
Outpatients | 2 | 2021 | 1600 | 0.540 |
Why?
|
History, 18th Century | 4 | 2019 | 206 | 0.540 |
Why?
|
Allied Health Personnel | 1 | 2018 | 156 | 0.540 |
Why?
|
Sarcoma, Kaposi | 1 | 2019 | 376 | 0.540 |
Why?
|
Ambulatory Care Facilities | 2 | 2023 | 939 | 0.540 |
Why?
|
Erythema | 1 | 2018 | 261 | 0.530 |
Why?
|
Delivery of Health Care | 4 | 2023 | 5367 | 0.530 |
Why?
|
Eosinophilia | 1 | 2021 | 556 | 0.530 |
Why?
|
Computer Security | 1 | 2018 | 261 | 0.530 |
Why?
|
Cellulitis | 2 | 2015 | 206 | 0.520 |
Why?
|
Delayed Diagnosis | 1 | 2020 | 467 | 0.520 |
Why?
|
Needlestick Injuries | 1 | 2016 | 71 | 0.510 |
Why?
|
Necrobiotic Xanthogranuloma | 1 | 2015 | 9 | 0.510 |
Why?
|
Cephalexin | 1 | 2015 | 37 | 0.500 |
Why?
|
Medical Staff, Hospital | 1 | 2019 | 603 | 0.500 |
Why?
|
Ketones | 1 | 2016 | 183 | 0.490 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2023 | 951 | 0.490 |
Why?
|
Carcinogens | 1 | 2017 | 453 | 0.490 |
Why?
|
Immune Reconstitution Inflammatory Syndrome | 1 | 2015 | 61 | 0.490 |
Why?
|
Quality of Life | 6 | 2023 | 13490 | 0.490 |
Why?
|
Comorbidity | 3 | 2024 | 10590 | 0.480 |
Why?
|
Pandemics | 8 | 2023 | 8747 | 0.480 |
Why?
|
Renal Dialysis | 1 | 2024 | 1791 | 0.480 |
Why?
|
Physicians, Primary Care | 2 | 2021 | 624 | 0.480 |
Why?
|
Triamcinolone Acetonide | 1 | 2015 | 105 | 0.480 |
Why?
|
Geriatrics | 1 | 2019 | 394 | 0.470 |
Why?
|
Internet | 3 | 2024 | 3110 | 0.470 |
Why?
|
History, 19th Century | 4 | 2019 | 714 | 0.470 |
Why?
|
Miliaria | 1 | 2014 | 6 | 0.470 |
Why?
|
Bibliometrics | 1 | 2018 | 354 | 0.470 |
Why?
|
Male | 51 | 2024 | 364731 | 0.460 |
Why?
|
Bookbinding | 1 | 2014 | 1 | 0.460 |
Why?
|
Salivary Gland Neoplasms | 1 | 2018 | 306 | 0.460 |
Why?
|
Tanning | 1 | 2014 | 12 | 0.460 |
Why?
|
Neurodermatitis | 1 | 2014 | 8 | 0.460 |
Why?
|
Phototherapy | 3 | 2024 | 368 | 0.460 |
Why?
|
Garlic | 1 | 2014 | 28 | 0.450 |
Why?
|
Biomedical Research | 3 | 2020 | 3463 | 0.450 |
Why?
|
Euphorbia | 1 | 2013 | 1 | 0.450 |
Why?
|
Occlusive Dressings | 1 | 2014 | 52 | 0.450 |
Why?
|
Arsenic | 1 | 2017 | 358 | 0.450 |
Why?
|
Lichen Planus | 1 | 2014 | 70 | 0.450 |
Why?
|
Physician's Role | 1 | 2020 | 925 | 0.440 |
Why?
|
Pharyngitis | 1 | 2015 | 222 | 0.440 |
Why?
|
Myelodysplastic Syndromes | 1 | 2024 | 1399 | 0.440 |
Why?
|
Internal Medicine | 1 | 2021 | 1064 | 0.440 |
Why?
|
Hypopigmentation | 1 | 2013 | 43 | 0.440 |
Why?
|
Nose Diseases | 1 | 2014 | 78 | 0.440 |
Why?
|
Plant Preparations | 1 | 2014 | 94 | 0.430 |
Why?
|
Azithromycin | 1 | 2014 | 201 | 0.430 |
Why?
|
Medicare | 7 | 2023 | 6809 | 0.430 |
Why?
|
Exons | 1 | 2019 | 2394 | 0.430 |
Why?
|
Data Interpretation, Statistical | 1 | 2023 | 2709 | 0.430 |
Why?
|
Skin Diseases, Vascular | 1 | 2013 | 41 | 0.420 |
Why?
|
Burns, Chemical | 1 | 2014 | 123 | 0.420 |
Why?
|
Diabetic Ketoacidosis | 1 | 2016 | 257 | 0.420 |
Why?
|
Natural Language Processing | 1 | 2022 | 1203 | 0.410 |
Why?
|
Diterpenes | 1 | 2013 | 170 | 0.410 |
Why?
|
Keratosis, Actinic | 1 | 2013 | 71 | 0.410 |
Why?
|
Patient Satisfaction | 3 | 2022 | 3490 | 0.410 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 686 | 0.410 |
Why?
|
Radiotherapy | 2 | 2019 | 1502 | 0.410 |
Why?
|
Triage | 1 | 2019 | 997 | 0.400 |
Why?
|
Neoplasms, Second Primary | 1 | 2020 | 1061 | 0.400 |
Why?
|
Cytosine | 1 | 2013 | 213 | 0.400 |
Why?
|
Acute Disease | 4 | 2023 | 7243 | 0.400 |
Why?
|
Sex Characteristics | 1 | 2023 | 2649 | 0.400 |
Why?
|
Hospitalization | 6 | 2023 | 10840 | 0.400 |
Why?
|
Reimbursement Mechanisms | 1 | 2018 | 670 | 0.400 |
Why?
|
Radiation Injuries | 1 | 2019 | 1198 | 0.390 |
Why?
|
Physicians | 5 | 2022 | 4598 | 0.390 |
Why?
|
Anti-Bacterial Agents | 4 | 2021 | 7477 | 0.390 |
Why?
|
Bone Marrow Transplantation | 2 | 2019 | 2709 | 0.390 |
Why?
|
Inappropriate Prescribing | 1 | 2014 | 212 | 0.390 |
Why?
|
Neoplasms | 5 | 2023 | 22371 | 0.390 |
Why?
|
Periodicals as Topic | 2 | 2020 | 1465 | 0.390 |
Why?
|
Hand Dermatoses | 3 | 2017 | 61 | 0.390 |
Why?
|
Phytotherapy | 1 | 2014 | 298 | 0.380 |
Why?
|
Enterocolitis, Pseudomembranous | 1 | 2013 | 264 | 0.380 |
Why?
|
Sodium Chloride | 1 | 2014 | 584 | 0.380 |
Why?
|
Female | 43 | 2024 | 397187 | 0.380 |
Why?
|
Homosexuality, Male | 1 | 2019 | 1344 | 0.380 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 1 | 2013 | 168 | 0.380 |
Why?
|
Protein Kinase Inhibitors | 2 | 2018 | 5704 | 0.380 |
Why?
|
Hypoglycemic Agents | 1 | 2024 | 3109 | 0.370 |
Why?
|
Carcinoma, Merkel Cell | 1 | 2015 | 329 | 0.370 |
Why?
|
Physicians, Women | 1 | 2017 | 517 | 0.370 |
Why?
|
Health Status Disparities | 1 | 2023 | 1885 | 0.370 |
Why?
|
Middle Aged | 32 | 2024 | 223487 | 0.370 |
Why?
|
Severe Combined Immunodeficiency | 1 | 2013 | 235 | 0.370 |
Why?
|
Vascular Diseases | 1 | 2019 | 1162 | 0.370 |
Why?
|
Streptococcal Infections | 1 | 2015 | 619 | 0.370 |
Why?
|
Tretinoin | 1 | 2014 | 525 | 0.370 |
Why?
|
Endothelium, Vascular | 2 | 2022 | 4428 | 0.370 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2015 | 667 | 0.360 |
Why?
|
Cultural Diversity | 3 | 2024 | 373 | 0.360 |
Why?
|
Crohn Disease | 1 | 2023 | 2295 | 0.350 |
Why?
|
Biological Products | 1 | 2020 | 947 | 0.350 |
Why?
|
Specialization | 1 | 2015 | 779 | 0.350 |
Why?
|
Antibodies, Monoclonal | 2 | 2024 | 9262 | 0.350 |
Why?
|
Diagnostic Errors | 2 | 2014 | 1281 | 0.340 |
Why?
|
Terminology as Topic | 1 | 2017 | 1542 | 0.340 |
Why?
|
Alopecia | 1 | 2014 | 416 | 0.340 |
Why?
|
Information Dissemination | 1 | 2018 | 1143 | 0.340 |
Why?
|
Retrospective Studies | 17 | 2024 | 81760 | 0.340 |
Why?
|
Plant Extracts | 1 | 2013 | 499 | 0.340 |
Why?
|
Influenza Vaccines | 1 | 2017 | 781 | 0.330 |
Why?
|
Probiotics | 1 | 2013 | 387 | 0.330 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2024 | 2298 | 0.330 |
Why?
|
Anus Neoplasms | 1 | 2013 | 336 | 0.330 |
Why?
|
Neurology | 1 | 2017 | 786 | 0.330 |
Why?
|
Oligopeptides | 1 | 2015 | 1194 | 0.320 |
Why?
|
Vaccination | 2 | 2022 | 3437 | 0.320 |
Why?
|
Leadership | 2 | 2021 | 1397 | 0.320 |
Why?
|
Sepsis | 1 | 2023 | 2608 | 0.320 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2014 | 454 | 0.320 |
Why?
|
Hospitals, General | 1 | 2013 | 809 | 0.320 |
Why?
|
Aged | 23 | 2024 | 171502 | 0.320 |
Why?
|
Health Policy | 2 | 2021 | 2697 | 0.320 |
Why?
|
Waldenstrom Macroglobulinemia | 1 | 2018 | 1077 | 0.320 |
Why?
|
Immunocompromised Host | 4 | 2023 | 863 | 0.320 |
Why?
|
Vasculitis | 1 | 2013 | 525 | 0.320 |
Why?
|
Hematopoietic Stem Cell Transplantation | 3 | 2017 | 5717 | 0.310 |
Why?
|
Health Services Accessibility | 3 | 2023 | 5520 | 0.310 |
Why?
|
Cicatrix | 1 | 2014 | 798 | 0.310 |
Why?
|
Mental Health | 1 | 2023 | 3275 | 0.310 |
Why?
|
Hematologic Neoplasms | 1 | 2020 | 1907 | 0.300 |
Why?
|
Immunotherapy, Adoptive | 1 | 2018 | 1512 | 0.300 |
Why?
|
Administration, Topical | 3 | 2015 | 704 | 0.300 |
Why?
|
Sex Factors | 5 | 2021 | 10632 | 0.300 |
Why?
|
Medical Oncology | 1 | 2020 | 2346 | 0.300 |
Why?
|
Pyrazoles | 1 | 2018 | 2028 | 0.290 |
Why?
|
Pyrimidines | 3 | 2021 | 3048 | 0.290 |
Why?
|
Sarcoma | 1 | 2019 | 1806 | 0.290 |
Why?
|
Gastrointestinal Tract | 1 | 2013 | 840 | 0.290 |
Why?
|
Comparative Effectiveness Research | 1 | 2013 | 714 | 0.290 |
Why?
|
Healthcare Disparities | 1 | 2023 | 3415 | 0.280 |
Why?
|
Combined Modality Therapy | 5 | 2024 | 8542 | 0.280 |
Why?
|
Interviews as Topic | 1 | 2015 | 2741 | 0.280 |
Why?
|
Graft vs Host Disease | 3 | 2017 | 3049 | 0.280 |
Why?
|
Breast Neoplasms | 3 | 2020 | 21207 | 0.280 |
Why?
|
Diarrhea | 1 | 2013 | 1320 | 0.270 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2020 | 4058 | 0.270 |
Why?
|
United States Department of Veterans Affairs | 1 | 2012 | 937 | 0.270 |
Why?
|
Hepatitis C, Chronic | 1 | 2015 | 1032 | 0.270 |
Why?
|
Interleukin-2 | 1 | 2013 | 1895 | 0.270 |
Why?
|
Adult | 24 | 2024 | 223646 | 0.270 |
Why?
|
Attitude of Health Personnel | 2 | 2019 | 3929 | 0.260 |
Why?
|
Authorship | 2 | 2020 | 289 | 0.260 |
Why?
|
Administration, Cutaneous | 2 | 2021 | 716 | 0.260 |
Why?
|
Diagnosis, Differential | 5 | 2022 | 13013 | 0.260 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2013 | 1628 | 0.250 |
Why?
|
Case-Control Studies | 4 | 2024 | 22290 | 0.250 |
Why?
|
Patient Education as Topic | 3 | 2025 | 2337 | 0.250 |
Why?
|
Psychiatry | 1 | 2017 | 1716 | 0.240 |
Why?
|
Health Expenditures | 1 | 2018 | 2389 | 0.240 |
Why?
|
Accreditation | 2 | 2024 | 477 | 0.230 |
Why?
|
RNA, Small Interfering | 1 | 2013 | 3428 | 0.230 |
Why?
|
Medicine | 3 | 2022 | 945 | 0.230 |
Why?
|
Efficiency, Organizational | 2 | 2019 | 697 | 0.230 |
Why?
|
Treatment Outcome | 11 | 2023 | 65379 | 0.230 |
Why?
|
Enterovirus | 1 | 2024 | 69 | 0.220 |
Why?
|
Liver Neoplasms | 1 | 2020 | 4363 | 0.220 |
Why?
|
Prostatectomy | 1 | 2012 | 1786 | 0.220 |
Why?
|
Protective Clothing | 1 | 2024 | 103 | 0.220 |
Why?
|
Immunotherapy | 3 | 2023 | 4754 | 0.210 |
Why?
|
Sunscreening Agents | 1 | 2024 | 139 | 0.210 |
Why?
|
School Admission Criteria | 1 | 2024 | 107 | 0.210 |
Why?
|
Fellowships and Scholarships | 2 | 2023 | 1135 | 0.210 |
Why?
|
Prurigo | 1 | 2023 | 26 | 0.210 |
Why?
|
Antineoplastic Agents | 4 | 2024 | 13677 | 0.210 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2021 | 11878 | 0.200 |
Why?
|
Biopsy, Needle | 2 | 2020 | 1623 | 0.200 |
Why?
|
Drug Labeling | 1 | 2025 | 250 | 0.200 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2023 | 412 | 0.200 |
Why?
|
Lung Neoplasms | 2 | 2019 | 13586 | 0.200 |
Why?
|
Clinical Trials as Topic | 2 | 2015 | 8052 | 0.200 |
Why?
|
Ointments | 1 | 2021 | 58 | 0.190 |
Why?
|
Simuliidae | 1 | 2021 | 5 | 0.190 |
Why?
|
Play and Playthings | 1 | 2021 | 85 | 0.190 |
Why?
|
Confidence Intervals | 2 | 2018 | 2923 | 0.190 |
Why?
|
Photography | 1 | 2024 | 537 | 0.190 |
Why?
|
Hair Removal | 1 | 2021 | 41 | 0.190 |
Why?
|
Nonprescription Drugs | 1 | 2022 | 119 | 0.180 |
Why?
|
Insect Bites and Stings | 1 | 2021 | 72 | 0.180 |
Why?
|
T-Lymphocytes | 1 | 2018 | 10266 | 0.180 |
Why?
|
Postoperative Complications | 3 | 2021 | 15833 | 0.180 |
Why?
|
Isotretinoin | 1 | 2022 | 134 | 0.180 |
Why?
|
Teaching | 2 | 2020 | 1171 | 0.180 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 5432 | 0.180 |
Why?
|
Oncolytic Viruses | 1 | 2024 | 344 | 0.180 |
Why?
|
Faculty | 2 | 2022 | 383 | 0.170 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2024 | 12252 | 0.170 |
Why?
|
Skin Care | 1 | 2020 | 55 | 0.170 |
Why?
|
Antigens, CD34 | 1 | 2022 | 657 | 0.170 |
Why?
|
Access to Information | 1 | 2023 | 317 | 0.170 |
Why?
|
Program Evaluation | 3 | 2019 | 2507 | 0.160 |
Why?
|
History, 20th Century | 2 | 2017 | 2766 | 0.160 |
Why?
|
Southeastern United States | 1 | 2019 | 93 | 0.160 |
Why?
|
Hospitals, Special | 1 | 2019 | 90 | 0.160 |
Why?
|
Insurance | 1 | 2021 | 115 | 0.160 |
Why?
|
Automation | 1 | 2021 | 589 | 0.160 |
Why?
|
Fatal Outcome | 2 | 2014 | 1836 | 0.160 |
Why?
|
Hyperplasia | 1 | 2022 | 1151 | 0.160 |
Why?
|
Electronic Health Records | 4 | 2021 | 4887 | 0.160 |
Why?
|
Information Seeking Behavior | 1 | 2020 | 116 | 0.160 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2023 | 388 | 0.150 |
Why?
|
Personal Autonomy | 1 | 2021 | 315 | 0.150 |
Why?
|
T-Cell Antigen Receptor Specificity | 1 | 2018 | 89 | 0.150 |
Why?
|
Physician Executives | 1 | 2019 | 140 | 0.150 |
Why?
|
Community-Institutional Relations | 1 | 2020 | 209 | 0.150 |
Why?
|
Prescriptions | 1 | 2021 | 388 | 0.150 |
Why?
|
Alopecia Areata | 1 | 2021 | 130 | 0.150 |
Why?
|
Back | 1 | 2018 | 64 | 0.150 |
Why?
|
Creatinine | 1 | 2024 | 1918 | 0.150 |
Why?
|
Africa South of the Sahara | 1 | 2021 | 752 | 0.150 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2013 | 9419 | 0.150 |
Why?
|
Arthritis, Rheumatoid | 1 | 2013 | 3781 | 0.150 |
Why?
|
Paris | 1 | 2017 | 40 | 0.150 |
Why?
|
Light | 1 | 2023 | 1355 | 0.140 |
Why?
|
Biomedical Technology | 1 | 2020 | 210 | 0.140 |
Why?
|
Syndrome | 1 | 2024 | 3273 | 0.140 |
Why?
|
Personal Satisfaction | 1 | 2022 | 643 | 0.140 |
Why?
|
Public Opinion | 1 | 2021 | 486 | 0.140 |
Why?
|
Scalp Dermatoses | 1 | 2017 | 44 | 0.140 |
Why?
|
Child | 7 | 2023 | 80917 | 0.140 |
Why?
|
Austria | 1 | 2017 | 208 | 0.140 |
Why?
|
Vaccines, Inactivated | 1 | 2017 | 186 | 0.130 |
Why?
|
Arm | 1 | 2019 | 591 | 0.130 |
Why?
|
Iatrogenic Disease | 1 | 2020 | 552 | 0.130 |
Why?
|
Dermatitis | 1 | 2018 | 203 | 0.130 |
Why?
|
Hospitals, Teaching | 1 | 2021 | 1157 | 0.130 |
Why?
|
3-Hydroxybutyric Acid | 1 | 2016 | 72 | 0.130 |
Why?
|
Young Adult | 6 | 2024 | 60066 | 0.130 |
Why?
|
Efficiency | 1 | 2019 | 479 | 0.130 |
Why?
|
Antistreptolysin | 1 | 2015 | 6 | 0.130 |
Why?
|
Mutation | 4 | 2024 | 30237 | 0.130 |
Why?
|
England | 1 | 2017 | 533 | 0.130 |
Why?
|
Students, Dental | 2 | 2015 | 171 | 0.130 |
Why?
|
Calcifediol | 1 | 2017 | 160 | 0.130 |
Why?
|
Technology | 1 | 2018 | 296 | 0.130 |
Why?
|
Foot Dermatoses | 1 | 2016 | 46 | 0.130 |
Why?
|
Databases as Topic | 1 | 2017 | 472 | 0.130 |
Why?
|
Data Collection | 2 | 2023 | 3326 | 0.130 |
Why?
|
Mentors | 1 | 2021 | 671 | 0.130 |
Why?
|
Disease Susceptibility | 2 | 2020 | 1793 | 0.120 |
Why?
|
Uncertainty | 1 | 2020 | 769 | 0.120 |
Why?
|
Pseudomonas aeruginosa | 1 | 2023 | 1276 | 0.120 |
Why?
|
Antigens, CD19 | 1 | 2018 | 446 | 0.120 |
Why?
|
Embolism, Cholesterol | 1 | 2015 | 32 | 0.120 |
Why?
|
Goals | 1 | 2020 | 717 | 0.120 |
Why?
|
Seasons | 1 | 2021 | 1524 | 0.120 |
Why?
|
Time Factors | 5 | 2020 | 40220 | 0.120 |
Why?
|
Clobetasol | 1 | 2015 | 33 | 0.120 |
Why?
|
Connective Tissue Diseases | 1 | 2018 | 285 | 0.120 |
Why?
|
Glomerular Filtration Rate | 1 | 2024 | 2227 | 0.120 |
Why?
|
Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2015 | 42 | 0.120 |
Why?
|
Methylmethacrylate | 1 | 2014 | 39 | 0.120 |
Why?
|
Leg | 1 | 2019 | 1088 | 0.120 |
Why?
|
United States Food and Drug Administration | 3 | 2025 | 1673 | 0.120 |
Why?
|
Facial Dermatoses | 1 | 2015 | 87 | 0.120 |
Why?
|
Inpatients | 2 | 2023 | 2566 | 0.120 |
Why?
|
Clostridium Infections | 1 | 2021 | 562 | 0.120 |
Why?
|
Publishing | 1 | 2021 | 837 | 0.120 |
Why?
|
Cardiovascular Diseases | 1 | 2020 | 15662 | 0.120 |
Why?
|
Naturopathy | 1 | 2014 | 13 | 0.110 |
Why?
|
Child, Preschool | 5 | 2023 | 42669 | 0.110 |
Why?
|
Herpesvirus 1, Human | 1 | 2020 | 743 | 0.110 |
Why?
|
Social Class | 1 | 2023 | 2008 | 0.110 |
Why?
|
Blood Transfusion | 1 | 2021 | 1309 | 0.110 |
Why?
|
Facial Neoplasms | 1 | 2015 | 126 | 0.110 |
Why?
|
Drug Therapy, Combination | 2 | 2015 | 6316 | 0.110 |
Why?
|
Electrons | 1 | 2015 | 264 | 0.110 |
Why?
|
Keratosis | 1 | 2014 | 81 | 0.110 |
Why?
|
Massachusetts | 2 | 2019 | 8890 | 0.110 |
Why?
|
Models, Economic | 1 | 2018 | 719 | 0.110 |
Why?
|
Purpura | 1 | 2014 | 117 | 0.110 |
Why?
|
Leg Ulcer | 1 | 2014 | 71 | 0.110 |
Why?
|
Blister | 1 | 2014 | 88 | 0.110 |
Why?
|
Dermoscopy | 1 | 2014 | 73 | 0.110 |
Why?
|
Calciphylaxis | 1 | 2015 | 129 | 0.110 |
Why?
|
Heterozygote | 1 | 2020 | 2798 | 0.110 |
Why?
|
Carcinoid Tumor | 1 | 2015 | 225 | 0.110 |
Why?
|
Lower Extremity | 1 | 2021 | 1217 | 0.110 |
Why?
|
Piperidines | 2 | 2021 | 1667 | 0.110 |
Why?
|
Educational Status | 2 | 2018 | 2515 | 0.110 |
Why?
|
Hair Color | 1 | 2013 | 131 | 0.110 |
Why?
|
Biopsy | 3 | 2014 | 6792 | 0.110 |
Why?
|
Staff Development | 1 | 2015 | 231 | 0.110 |
Why?
|
Clinical Competence | 3 | 2024 | 4858 | 0.110 |
Why?
|
Sampling Studies | 1 | 2014 | 615 | 0.110 |
Why?
|
Ribavirin | 1 | 2015 | 395 | 0.100 |
Why?
|
Needs Assessment | 1 | 2019 | 1141 | 0.100 |
Why?
|
Hydroxyurea | 1 | 2014 | 284 | 0.100 |
Why?
|
Granuloma | 1 | 2015 | 329 | 0.100 |
Why?
|
Brain Neoplasms | 1 | 2014 | 9118 | 0.100 |
Why?
|
Mucormycosis | 1 | 2014 | 102 | 0.100 |
Why?
|
Fee-for-Service Plans | 1 | 2018 | 713 | 0.100 |
Why?
|
Diplopia | 1 | 2014 | 217 | 0.100 |
Why?
|
Dermatitis, Allergic Contact | 1 | 2014 | 112 | 0.100 |
Why?
|
Hemianopsia | 1 | 2014 | 121 | 0.100 |
Why?
|
Education, Dental | 1 | 2015 | 220 | 0.100 |
Why?
|
Algorithms | 3 | 2022 | 14164 | 0.100 |
Why?
|
Polycythemia Vera | 1 | 2014 | 160 | 0.100 |
Why?
|
Adenine | 1 | 2018 | 995 | 0.100 |
Why?
|
Cost-Benefit Analysis | 2 | 2017 | 5536 | 0.100 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3115 | 0.100 |
Why?
|
Allergy and Immunology | 1 | 2014 | 175 | 0.100 |
Why?
|
Health Behavior | 1 | 2024 | 2650 | 0.100 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3238 | 0.100 |
Why?
|
Hospitals | 2 | 2023 | 3886 | 0.100 |
Why?
|
Necrosis | 2 | 2014 | 1616 | 0.100 |
Why?
|
Respiratory Insufficiency | 1 | 2021 | 1240 | 0.100 |
Why?
|
Inflammation | 2 | 2023 | 10873 | 0.100 |
Why?
|
Students | 1 | 2022 | 1744 | 0.100 |
Why?
|
Skin Ulcer | 1 | 2013 | 130 | 0.100 |
Why?
|
Kidney Failure, Chronic | 1 | 2024 | 2496 | 0.100 |
Why?
|
Gait Disorders, Neurologic | 1 | 2014 | 243 | 0.100 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2024 | 2195 | 0.100 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2024 | 4055 | 0.100 |
Why?
|
Hot Temperature | 1 | 2018 | 1440 | 0.090 |
Why?
|
Cholangiocarcinoma | 1 | 2017 | 561 | 0.090 |
Why?
|
Bile Duct Neoplasms | 1 | 2017 | 614 | 0.090 |
Why?
|
Thalidomide | 1 | 2016 | 886 | 0.090 |
Why?
|
Drug Prescriptions | 1 | 2020 | 1668 | 0.090 |
Why?
|
Opportunistic Infections | 1 | 2014 | 375 | 0.090 |
Why?
|
Disease Management | 2 | 2019 | 2535 | 0.090 |
Why?
|
Qualitative Research | 1 | 2022 | 3140 | 0.090 |
Why?
|
Prognosis | 5 | 2019 | 30009 | 0.090 |
Why?
|
Methotrexate | 1 | 2017 | 1721 | 0.090 |
Why?
|
Immunohistochemistry | 2 | 2014 | 11095 | 0.090 |
Why?
|
Aged, 80 and over | 5 | 2024 | 59626 | 0.090 |
Why?
|
Developing Countries | 1 | 2023 | 2910 | 0.090 |
Why?
|
Melanocytes | 1 | 2013 | 509 | 0.090 |
Why?
|
Nephrology | 1 | 2014 | 270 | 0.090 |
Why?
|
Quality Indicators, Health Care | 1 | 2020 | 1805 | 0.080 |
Why?
|
Wound Healing | 1 | 2021 | 2815 | 0.080 |
Why?
|
Occupational Health | 1 | 2016 | 812 | 0.080 |
Why?
|
Hospitals, Veterans | 1 | 2012 | 395 | 0.080 |
Why?
|
Low Back Pain | 1 | 2018 | 990 | 0.080 |
Why?
|
Quality Improvement | 1 | 2024 | 3857 | 0.080 |
Why?
|
Decision Making | 1 | 2023 | 3953 | 0.080 |
Why?
|
Prostatic Neoplasms | 1 | 2012 | 11101 | 0.080 |
Why?
|
HIV Infections | 1 | 2015 | 17569 | 0.080 |
Why?
|
Gastroenterology | 1 | 2015 | 593 | 0.080 |
Why?
|
Kidney | 1 | 2024 | 7064 | 0.080 |
Why?
|
Brachytherapy | 1 | 2016 | 1220 | 0.080 |
Why?
|
Adrenal Cortex Hormones | 1 | 2017 | 1886 | 0.080 |
Why?
|
Pilot Projects | 2 | 2021 | 8741 | 0.070 |
Why?
|
Public Health | 1 | 2021 | 2679 | 0.070 |
Why?
|
Anxiety | 1 | 2023 | 4672 | 0.070 |
Why?
|
Steroids | 1 | 2013 | 938 | 0.070 |
Why?
|
Pain | 1 | 2023 | 5099 | 0.070 |
Why?
|
Rheumatology | 1 | 2014 | 617 | 0.070 |
Why?
|
Lymphocyte Activation | 1 | 2018 | 5505 | 0.070 |
Why?
|
Education, Medical, Continuing | 1 | 2013 | 829 | 0.070 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2024 | 9016 | 0.070 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2015 | 957 | 0.070 |
Why?
|
Gene Silencing | 1 | 2013 | 1505 | 0.070 |
Why?
|
History, 21st Century | 1 | 2013 | 1573 | 0.070 |
Why?
|
Risk Factors | 5 | 2022 | 74944 | 0.070 |
Why?
|
Vitamin D Deficiency | 1 | 2017 | 1388 | 0.070 |
Why?
|
Hospital Mortality | 1 | 2021 | 5349 | 0.070 |
Why?
|
Cohort Studies | 2 | 2021 | 41753 | 0.070 |
Why?
|
Neoplasm Staging | 2 | 2020 | 11244 | 0.070 |
Why?
|
Prevalence | 1 | 2024 | 15869 | 0.070 |
Why?
|
Warfarin | 1 | 2015 | 1493 | 0.070 |
Why?
|
Gastrointestinal Diseases | 1 | 2015 | 1205 | 0.070 |
Why?
|
SEER Program | 1 | 2012 | 1444 | 0.070 |
Why?
|
Incidence | 4 | 2021 | 21538 | 0.070 |
Why?
|
Cultural Competency | 1 | 2009 | 303 | 0.070 |
Why?
|
Drug Approval | 1 | 2013 | 821 | 0.070 |
Why?
|
India | 1 | 2013 | 2334 | 0.070 |
Why?
|
Molecular Targeted Therapy | 1 | 2017 | 2830 | 0.060 |
Why?
|
Drug Administration Schedule | 1 | 2014 | 4861 | 0.060 |
Why?
|
Reproducibility of Results | 1 | 2024 | 20225 | 0.060 |
Why?
|
Genetic Predisposition to Disease | 2 | 2020 | 18065 | 0.060 |
Why?
|
Anti-Inflammatory Agents | 1 | 2015 | 1810 | 0.060 |
Why?
|
RNA Interference | 1 | 2013 | 2832 | 0.060 |
Why?
|
Stem Cell Transplantation | 1 | 2013 | 1599 | 0.060 |
Why?
|
Radiography | 1 | 2015 | 6986 | 0.060 |
Why?
|
Immunosuppressive Agents | 1 | 2017 | 4206 | 0.060 |
Why?
|
Radioimmunotherapy | 1 | 2024 | 93 | 0.060 |
Why?
|
Propensity Score | 1 | 2012 | 1969 | 0.060 |
Why?
|
Odds Ratio | 1 | 2016 | 9669 | 0.060 |
Why?
|
Diet | 1 | 2022 | 8089 | 0.050 |
Why?
|
Patient-Centered Care | 1 | 2013 | 1444 | 0.050 |
Why?
|
Cytokines | 1 | 2018 | 7452 | 0.050 |
Why?
|
Practice Guidelines as Topic | 1 | 2020 | 7454 | 0.050 |
Why?
|
Hematologic Tests | 1 | 2024 | 239 | 0.050 |
Why?
|
Severity of Illness Index | 2 | 2021 | 15949 | 0.050 |
Why?
|
Cardiology | 1 | 2014 | 1702 | 0.050 |
Why?
|
Lymph Nodes | 1 | 2014 | 3474 | 0.050 |
Why?
|
Alleles | 1 | 2013 | 6894 | 0.050 |
Why?
|
Primary Health Care | 1 | 2019 | 4746 | 0.050 |
Why?
|
MutS Homolog 2 Protein | 1 | 2023 | 200 | 0.050 |
Why?
|
Patient Care Team | 1 | 2013 | 2523 | 0.050 |
Why?
|
Ultrasonography | 1 | 2015 | 6004 | 0.050 |
Why?
|
Disease Progression | 2 | 2016 | 13668 | 0.050 |
Why?
|
Clindamycin | 1 | 2021 | 138 | 0.050 |
Why?
|
Antiviral Agents | 1 | 2013 | 3072 | 0.050 |
Why?
|
Phenotype | 1 | 2019 | 16726 | 0.040 |
Why?
|
Arteriosclerosis | 1 | 2005 | 1055 | 0.040 |
Why?
|
Peer Review | 1 | 2022 | 218 | 0.040 |
Why?
|
Adolescent | 4 | 2021 | 89169 | 0.040 |
Why?
|
Publications | 1 | 2022 | 195 | 0.040 |
Why?
|
DNA Mismatch Repair | 1 | 2023 | 431 | 0.040 |
Why?
|
Anticoagulants | 1 | 2015 | 4850 | 0.040 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2014 | 3252 | 0.040 |
Why?
|
Quality of Health Care | 1 | 2013 | 4310 | 0.040 |
Why?
|
Risk Assessment | 2 | 2017 | 24318 | 0.040 |
Why?
|
Animals | 3 | 2021 | 169285 | 0.040 |
Why?
|
Logistic Models | 1 | 2012 | 13290 | 0.030 |
Why?
|
Hospitalists | 1 | 2020 | 298 | 0.030 |
Why?
|
Advisory Committees | 1 | 2020 | 796 | 0.030 |
Why?
|
Self Efficacy | 1 | 2020 | 643 | 0.030 |
Why?
|
Hand | 1 | 2021 | 913 | 0.030 |
Why?
|
Trans-Activators | 1 | 2005 | 2857 | 0.030 |
Why?
|
Registries | 1 | 2012 | 8375 | 0.030 |
Why?
|
Educational Measurement | 2 | 2015 | 1260 | 0.030 |
Why?
|
Gender Identity | 1 | 2021 | 770 | 0.030 |
Why?
|
Signal Transduction | 1 | 2018 | 23648 | 0.030 |
Why?
|
Follow-Up Studies | 2 | 2014 | 39354 | 0.030 |
Why?
|
International Classification of Diseases | 1 | 2021 | 937 | 0.030 |
Why?
|
Retreatment | 1 | 2016 | 598 | 0.030 |
Why?
|
Pyrroles | 1 | 2021 | 1124 | 0.030 |
Why?
|
Interdisciplinary Communication | 1 | 2020 | 937 | 0.030 |
Why?
|
Germ-Line Mutation | 1 | 2023 | 1885 | 0.030 |
Why?
|
Boston | 2 | 2020 | 9374 | 0.030 |
Why?
|
Consensus | 1 | 2024 | 3211 | 0.030 |
Why?
|
Thigh | 1 | 2015 | 239 | 0.030 |
Why?
|
New England | 1 | 2017 | 1058 | 0.030 |
Why?
|
Whole-Body Irradiation | 1 | 2014 | 435 | 0.030 |
Why?
|
Rural Population | 1 | 2022 | 2325 | 0.020 |
Why?
|
Fingers | 1 | 2014 | 511 | 0.020 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 3251 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2021 | 2726 | 0.020 |
Why?
|
Antifungal Agents | 1 | 2014 | 761 | 0.020 |
Why?
|
Triazoles | 1 | 2014 | 904 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2023 | 14729 | 0.020 |
Why?
|
Societies, Medical | 1 | 2020 | 3968 | 0.020 |
Why?
|
Length of Stay | 1 | 2021 | 6498 | 0.020 |
Why?
|
Problem-Based Learning | 1 | 2009 | 360 | 0.020 |
Why?
|
Feedback | 1 | 2009 | 799 | 0.020 |
Why?
|
Learning | 1 | 2015 | 1759 | 0.020 |
Why?
|
Databases, Factual | 1 | 2021 | 8080 | 0.020 |
Why?
|
Umbilical Veins | 1 | 2005 | 425 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2021 | 15453 | 0.010 |
Why?
|
Protective Agents | 1 | 2005 | 151 | 0.010 |
Why?
|
Survivors | 1 | 2014 | 2381 | 0.010 |
Why?
|
Kruppel-Like Transcription Factors | 1 | 2005 | 507 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2014 | 10763 | 0.010 |
Why?
|
Survival Rate | 1 | 2014 | 12840 | 0.010 |
Why?
|
Infant | 1 | 2021 | 36535 | 0.010 |
Why?
|
Kinetics | 1 | 2005 | 6330 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2005 | 12801 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2005 | 11930 | 0.000 |
Why?
|